ライフサイエンスコーパス: bone pain

1 en dosing and the role of BMAs in control of bone pain.

2 ave been studied in patients with metastatic bone pain.

3 symptoms including fatigue, weight loss, and bone pain.

4 d treatment options for relieving metastatic bone pain.

5 d worse survival outcomes than those without bone pain.

6 oplasia of B plasma cells that often induces bone pain.

7 f clinical relevance, mechanisms for central bone pain.

8 ulator of tumor growth, bone remodeling, and bone pain.

9 enomegaly, lactate dehydrogenase levels, and bone pain.

10 idence and severity of pegfilgrastim-induced bone pain.

11 or ability to prevent pegfilgrastim-induced bone pain.

12 as initial imaging studies in patients with bone pain.

13 isms of chronic bone pain and cancer-induced bone pain.

14 kets, limb deformities, muscle weakness, and bone pain.

15 included minor injection site reactions and bone pain.

16 r, 186Re, and 153Sm) have been used to treat bone pain.

17 phonic acid (EDTMP), have been used to treat bone pain.

18 odest, and they should not be used alone for bone pain.

19 unotherapy and in radionuclide palliation of bone pain.

20 safe, but nearly all donors will experience bone pain, 1 in 4 will have significant headache, nausea

21 ] vs 18 [6%]), asthenia (16 [5%] vs 8 [3%]), bone pain (16 [5%] vs 5 [2%]), and febrile neutropenia (

22 Among the 23 patients with bone pain (31%), 39% reported complete resolution and 52

23 ost commonly reported with luspatercept were bone pain (35 [37%]), headache (29 [30%]), and arthralgi

24 with urticarial rash, fever, arthralgia, and bone pain; 47% reported weight loss, 40% fatigue, and 21

25 hrombosis (120 mg/m2), one grade 4 joint and bone pain (480 mg/m2), one thrombocytopenia (600 mg/m2)

26 cularly true for the skeletal-related events bone pain (5 years, 8.3% vs 2 years, 3.7%) and arthralgi

27 4%), fatigue (7%), thrombotic episodes (7%), bone pain (5%), and gastrointestinal disturbance (4%).

28 of 704 allocated ibandronic acid), increased bone pain (91 [corrected] [13%] vs 85 [corrected] [12%])

29 satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers

30 , 3.3-4.2 years) in patients without initial bone pain (adjusted hazard ratio [AHR], 1.46; 95% CI, 1.

31 15 patients required narcotic analgesics for bone pain; after treatment, eight (53%) discontinued the

32 6.6 years to NR) in patients without initial bone pain (AHR, 1.66; 95% CI, 1.34-2.05; P < .001).

33 Bone pain, analgesic use, bone biochemical markers, perf

34 = 12 mg per deciliter [3.0 mmol per liter]), bone pain, analgesic-drug use, performance status, and q

35 Twenty-six patients (37%) had bone pain and 37 patients (52%) had extensive disease.

36 nding of the molecular mechanisms of chronic bone pain and cancer-induced bone pain.

37 generation and continuance of cancer-induced bone pain and discuss these in the context of understand

38 Severe bone pain and esophageal cancer have been described amon

39 line in BPI-SF worst pain, single-item worst bone pain and FACT-P Total Outcome Index (TOI) scale sco

40 toms attributable to metastatic disease (eg, bone pain and headache) or be diagnosed with incidentall

41 practice.An 84-year-old woman presented with bone pain and lytic bone lesions in April 2010.

42 ite the above replacement, she complained of bone pain and muscle weakness, and she continued to be v

43 (67.9% and 46.6%, respectively) followed by bone pain and myalgia (37.6% and 31.8%, respectively).

44 ved pamidronate had significant decreases in bone pain and no deterioration in performance status and

45 ften asymptomatic but can be associated with bone pain and other complications such as osteoarthritis

46 ed by extensive osteolysis leading to severe bone pain and pathologic fracture.

47 Bone pain and radiologic evidence of periostitis were ex

48 However, there are few data regarding bone pain and survival outcomes in the context of metast

49 mia in a 53 year old male who presented with bone-pain and B-symptoms and was found to have diffuse o

50 a decrease in skeletal events, palliation of bone pain, and a low profile of adverse reactions (which

51 deterioration in BPI-SF worst pain and worst bone pain, and assessment of the EQ-5D-5L pain and disco

52 line in BPI-SF worst pain, single-item worst bone pain, and FACT-P TOI remained stable across all vis

53 e [3%] vs 0), fatigue, hot flashes, myalgia, bone pain, and fractures (two [2%] vs 0 for each).

54 d diseases, including pathological fracture, bone pain, and hypercalcemia.

55 h nephrolithiasis, significant osteoporosis, bone pain, and in some cases constitutional symptoms sho

56 getic beta-particle emitters for alleviating bone pain, and possibly for other therapeutic applicatio

57 ng local symptoms (30%) such as pleuritis or bone pain; approximately 60% of patients with SCLC may b

58 Interventions for pegfilgrastim-induced bone pain are needed.

59 is primarily indicated for patients who have bone pain arising from increased metabolic activity in a

60 Adverse events of transient bone pain, arthralgia, dizziness, hypertension, and hype

61 he sensory characteristics of cancer-induced bone pain as a basis for better understanding and treati

62 We now view cancer-induced bone pain as a complex pain state involving components o

63 r a substantial advantage for alleviation of bone pain as well as for specifically irradiating metast

64 ons, including fractures, hypercalcemia, and bone pain, as well as reduced performance status and qua

65 study participants, 301 (23.5%) had baseline bone pain at MHSPC diagnosis and 896 (70.1%) did not.

66 mized clinical trial, patients with baseline bone pain at MHSPC diagnosis had worse survival outcomes

67 49 (52%) patients with bone pain at registration had complete resolution of pai

68 ing placebo, including a higher incidence of bone pain, bone fractures, and new-onset osteoporosis.

69 In a subgroup of patients with bone pain, CA 27.29 antigen level was found to identify

70 Palliation of bone pain can be achieved in men with androgen-independe

71 a result of osseous metastases and resulting bone pain can lead to significant debilitation.

72 iverse set of conditions, from joint pain to bone pain, chemotherapy-induced neuropathic pain, Fabry

73 Cancer-induced bone pain (CIBP) affects one third of patients with canc

74 Conservative debridement of necrotic bone, pain control, infection management, use of antimic

75 g: acute kidney injury, arterial thrombosis, bone pain, diarrhoea, myocardial infarction, pyrexia, re

76 cers, causing bone complications (fractures, bone pain, disability) that negatively affect the patien

77 Seventeen patients with bone pain due to metastasis were given three dose levels

78 olled trials were conducted in patients with bone pain due to metastatic prostate cancer, with diseas

79 sing Functional Assessment of Cancer Therapy-Bone Pain (FACT-BP) scores (scale, 0-60 points), improve

80 g acutely with non-specific symptoms such as bone pain, fever or swelling which are common in acute o

81 The principal toxicities were myalgias, bone pain, fever, nausea, and mild thrombocytopenia, but

82 History of bone pain, fractures, and avascular necrosis was found i

83 ter receiving 89Sr-chloride for treatment of bone pain from metastatic prostate carcinoma.

84 e is a useful intervention for patients with bone pain from metastatic prostatic cancer.

85 ntory-Short Form (BPI-SF), single-item worst bone pain, Functional Assessment of Cancer Therapy-Prost

86 grade 3 toxic events, including arthralgia, bone pain, generalised muscle weakness, syncope, and dys

87 .0 years (IQR, 2.5-5.4 years), patients with bone pain had median PFS of 1.3 years (95% CI, 1.1-1.7 y

88 most common grade 1 to 2 adverse events were bone pain, headache, and myalgia.

89 rms of pain, including musculoskeletal pain, bone pain, headache, arthralgia, and pain in extremity,

90 w promise in the treatment of cancer-induced bone pain, however further assessment of their effects o

91 in HR 0.90 [95% CI 0.62-1.32], p=0.30; worst bone pain HR 0.85 [0.59-1.22], p=0.18).

92 risks of external beam radiation therapy for bone pain (HR 0.67, 95% CI 0.53-0.85) and spinal cord co

93 On retrospective review, bone pain improved in 67% of evaluable patients, with a

94 to reversible panniculitis in 5 patients and bone pain in 1 patient.

95 And do bisphosphonates relieve bone pain in cancers other than breast cancer and myelom

96 wever further assessment of their effects on bone pain in genetically engineered animal models and ca

97 unseling, and indicate that the inclusion of bone pain in prognostic models of MHSPC may be warranted

98 Pharmaceutical therapy of bone pain includes nonsteroidal analgesics and opiates.

99 Treatment of bone pain includes nonsteroidal analgesics and opiates;

100 This information is crucial, since bone pain, including cancer-induced bone pain, is an are

101 74-year-old woman presented with multifocal bone pain, including pain in multiple ribs, bilateral sh

102 Bone pain is a common complication for terminal patients

103 Bone pain is a presenting feature of bone cancers such a

104 Pegfilgrastim-induced bone pain is a significant clinical problem that may res

105 Cancer-induced bone pain is characterized by moderate to severe ongoing

106 A multidisciplinary approach in treating bone pain is generally required, 1 which includes a comb

107 The presence of bone pain is significantly associated with worse overall

108 l, since bone pain, including cancer-induced bone pain, is an area of high importance in pain biology

109 therapy in relieving prostate cancer-induced bone pain, is that nearly all nerve fibers that innervat

110 significantly associated with baseline PSA, bone pain, liver disease, hemoglobin, alkaline phosphata

111 Current standards of care for cancer bone pain management should be applied at the onset of p

112 Analgesic therapies for myeloma-induced bone pain (MIBP) are limited and often ineffective, and

113 r, the mechanisms underlying myeloma-induced bone pain (MIBP) are mostly unknown.

114 haracterized by recurrent episodes of severe bone pain, multi-organ failure, and early mortality.

115 Bone pain, myalgia, presyncope, or fever occurred in 55%

116 erse events in all treatment groups included bone pain, nausea, anemia, and vomiting.

117 Obese donors experienced more bone pain (obese vs normal, OR=1.73) and heavy donors ha

118 resis-related AEs (20% vs 7%, P< .001), more bone pain (odds ratio [OR]=1.49), and higher rates of gr

119 two [1%]), dyspnoea (four [2%] vs one [1%]), bone pain (one [1%] vs four [2%]), congestive cardiac fa

120 in PSA levels coupled with either relief of bone pain or by a 50% decrease in measurable disease.

121 nefit compared with placebo in palliation of bone pain or reduction of SREs.

122 he use of external beam radiation to relieve bone pain, or occurrence of a new symptomatic pathologic

123 e review data regarding atrial fibrillation, bone pain, osteonecrosis of the jaw (ONJ), atypical frac

124 There was significantly less increase in bone pain (P=0.046) and deterioration of performance sta

125 ifferent and unique and may make it an ideal bone pain palliation agent.

126 riety of therapeutic applications, including bone pain palliation and intravascular radiation therapy

127 Among the four potential bone pain palliation radionuclides, 117mSn(4+)DTPA demon

128 ide therapies such as radioimmunotherapy and bone pain palliation.

129 es are needed to determine its exact role in bone pain palliation.

130 ytic bone destruction and its complications, bone pain, pathologic fractures, and hypercalcemia, are

131 ase and/or treatment of disease, and include bone pain, pathological fractures and spinal cord compre

132 were stratified by race (Black or other) and bone pain (present or absent).

133 For metastatic bone pain, providers should offer single-fraction radiot

134 l-world study, PARABO, investigated pain and bone pain-related quality of life in patients with mCRPC

135 Currently, the treatment of bone pain remains palliative at best with systemic thera

136 ticals have shown good efficacy in relieving bone pain secondary to bone metastasis.

137 d liver iron concentration (seven [2%]), and bone pain (seven [2%]); serious TEAEs occurred in 71 (23

138 Bone pain status was unavailable in 82 patients (6.4%).

139 ention-to-treat population who had available bone pain status were eligible and included in this seco

140 Greek patients had more bone pain than United States patients (60% v 30%, P = .0

141 flushing, palpitations, dyspepsia, diarrhea, bone pain) that can be severe and potentially life threa

142 ompared with patients who did not experience bone pain, those with baseline bone pain were younger (m

143 22 y) presenting with sickle cell-associated bone pain underwent 93 sequential examinations with 99mT

144 Bone pain, use of analgesic drugs, performance status, a

145 Bone pain, use of analgesics, quality of life, performan

146 Over the years, treatment of bone pain using bone-seeking radiopharmaceuticals has be

147 After adjustment, bone pain was associated with shorter PFS and OS.

148 Transient rash occurred on plerixafor, and bone pain was more common on G-CSF.

149 2 (CB(2)) receptors attenuate cancer-induced bone pain, we searched Medline, Web of Science and Scopu

150 Symptoms include chronic muscle and bone pain, weakness, and fatigue in association with a h

151 ild-to-moderate injection-site reactions and bone pain were more common in the sargramostim group, an

152 ot experience bone pain, those with baseline bone pain were younger (median age, 66.0 [IQR, 60.1-73.4

153 have metastasized to bone frequently induce bone pain which can be difficult to fully control as it

154 Thirty-one patients with metastatic bone pain who underwent FDG PET/computed tomography befo

155 amidronate (Aredia), will relieve metastatic bone pain with a consequent improvement in quality of li